Filter by: patients

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
ALS (Amyotrophic Lateral Sclerosis) 22 2 Efficacy_cant_tell
General health 17 1 Efficacy_cant_tell
Other 5 0
Fatigue 2 0
MS (Multiple Sclerosis) 2 1 Efficacy_slight
Parkinson's Disease 2 0

See all 26 patients currently taking Glyconutrients

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
0
Moderate
0
Mild
0
None
5

Reported Dosages

Frequently reported dosages based on patients currently taking Glyconutrients. See all 15 dosages

  daily 1 tbs. daily 2 tps. daily 2 tbs. daily 4 daily 4 mg daily 4 tps. daily 5 mg daily 500 mg daily 1,200 mg daily
  12 Number of Patients: 12 3 Number of Patients: 3 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2 3 Number of Patients: 3 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Glyconutrients (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 19   Did not seem to work: 73%
Expense 7   Expense: 27%
Other 4   Other: 15%
Personal research 2   Personal research: 8%
Doctor's advice 1   Doctor's advice: 4%

See all 26 patients who’ve stopped taking Glyconutrients

Currently Taking Glyconutrients

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Stopped Taking Glyconutrients

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Glyconutrients

Always
4 80%
Usually
1 20%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Glyconutrients

Very
2 40%
Somewhat
0 0%
A little
2 40%
Not at all
1 20%

Cost

Paid out of pocket

Cost of Glyconutrients

$200+
0 0%
$100-199
2 67%
$50-99
0 0%
$25-49
1 33%
< $25
0 0%

Report created on February 11, 2012.